Goldman Sachs analysts added UCB (UCBJF) to the firm’s European Conviction List as part of its monthly update. The firm believes UCB offers a “rare opportunity” within European biopharma to own a blockbuster launch.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF: